Physician profile
Joli E Shepard
NPI 1457793994
$2,417.45
in general payments reported to CMS, 2019-2025
14 companies · $977 in 2025
The $977 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $53.98 · 2021: $115 · 2022: $253 · 2023: $202 · 2024: $700 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,257.12 | 2020-2025 | Precision 1, Dailies Total1, Precision7 |
| Johnson & Johnson Vision Care, INC. | $343.23 | 2019-2025 | Acuvue |
| Abbvie INC. | $185.32 | 2022-2024 | Vuity, Lumigan |
| Glaukos Corporation | $177.37 | 2022-2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $132.98 | 2024-2025 | Infuse, Xiidra, Miebo |
| Genentech USA, INC. | $63.68 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.32 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $46.75 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $37.22 | 2021-2022 | |
| Dompe US, INC. | $31.07 | 2025 | Oxervate |
| Avedro INC. | $29.94 | 2019 | |
| Allergan, INC. | $22.74 | 2022 | |
| Kala Pharmaceuticals, INC. | $17.72 | 2022 | |
| Oyster Point Pharma, INC. | $15.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joli Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.